N/A
N=20
Community Exercise for Fall Risk in PD
Parkinson Disease · Fall · Exercise
Bottom Line
View on ClinicalTrials.gov: NCT05940077 ↗Enrolled (actual)
20
Serious AEs
0.0%
Results posted
Aug 2023
Primary outcome: Primary: Number of Falls Experienced During the Study Period as Reported by Self-report — 16; 7 self-reported falls
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Exercise (Behavioral)
- Age
- Adult, Older Adult · 30+ yrs
- Sex
- All
- Sponsor
- Idaho State University
- Primary completion
- Mar 2022
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Falls Experienced During the Study Period as Reported by Self-report |
16; 7 | — |
| SECONDARY TUG |
11.02; 8.13 | — |
| SECONDARY BBS |
40.47; 46.84 | — |
| SECONDARY ABC |
78.92; 86.05 | — |
| SECONDARY 5-STS |
15.58; 11.53 | — |
Summary
Parkinson's disease (PD) affects approximately 1 million people in the United States and causes significant fall risks. This study aims to develop a community-based exercise program that reduces falls in persons with PD. By combining individualized balance activities with group boxing training, the study seeks to identify modifiable risk factors, improve balance dysfunction, and reduce falls. The findings will inform clinical practice, offering a community-based exercise model to address the urgent need for effective fall prevention interventions in PD.
Eligibility Criteria
Inclusion Criteria
- A diagnosis of idiopathic PD; Male or female 30 years or older at time of PD diagnosis; Hoehn & Yahr (H&Y) stages 1.0-3.0; Ability to provide informed consent in accordance with Good Clinical Practice (GCP) and local regulations.
Exclusion Criteria
- Idiopathic PD H&Y stage 4-5, in order to constrain motor dysfunctions to mild-to-moderate PD; Confirmed or suspected atypical parkinsonian syndromes due to drugs, metabolic disorders, encephalitis, or degenerative diseases; Presence of definite dementia by Montreal Cognitive Assessment (MoCA <21); Central or peripheral nervous system disorders (other than PD); Myopathic disease (e.g. focal myopathy) that affects skeletal muscle structure/function; Severe cardiovascular disease that limits exercise abilities.
Data sourced from ClinicalTrials.gov (NCT05940077). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.